Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of ADO09 vs Insulin Lispro and Pramlintide/Human Insulin in T1D
NCT03916640Phase 1Completed
- Sponsor
- Adocia
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ADO09 in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Adocia. Primary endpoints: Maximum Plasma Concentration of Pramlintide, Area Under the Plasma Concentration-Time Curve of Pramlintide and 2 more. Started Jan 2019; status: completed.
02
Drugs
ADO09
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03916640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916640.